SLP trades 1.2% below Wall Street's consensus target of $18.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SLP achieves its forward estimates and maintains a stable P/E multiple of 21.1x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Simulations Plus, Inc. (SLP) has a Wall Street consensus price target of $18.50, based on estimates from 9 covering analysts. With the stock currently trading at $18.28, this represents a potential upside of +1.2%. The company has a market capitalization of $369M.
Analyst price targets range from a low of $18.50 to a high of $18.50, representing a 0% spread in expectations. The median target of $18.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 4 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, SLP trades at a trailing P/E of -5.7x and forward P/E of 21.1x. Analysts expect EPS to grow +128.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
VEEVVeeva Systems Inc. | $31.2B | $192.30 | $235.38 | +22.4% | Buy | 21.2x | 43 |
CERTCertara, Inc. | $1.1B | $7.17 | $9.00 | +25.5% | Buy | 18.7x | 16 |
SCYXSCYNEXIS, Inc. | $29M | $4.61 | — | — | — | — | — |
DSGNDesign Therapeutics, Inc. | $919M | $14.71 | $20.50 | +39.4% | Buy | — | 7 |
SDGRSchrödinger, Inc. | $1.2B | $16.49 | $18.00 | +9.2% | Buy | — | 12 |
RXRXRecursion Pharmaceuticals, Inc. | $1.7B | $3.84 | $5.50 | +43.2% | Hold | — | 10 |
ABSIAbsci Corporation | $1.8B | $11.33 | $12.40 | +9.4% | Buy | — | 13 |
TMOThermo Fisher Scientific Inc. | $192.0B | $516.62 | $592.45 | +14.7% | Buy | 20.8x | 42 |
AAgilent Technologies, Inc. | $37.0B | $131.14 | $154.75 | +18.0% | Buy | 21.7x | 41 |
CRLCharles River Laboratories International, Inc. | $11.0B | $228.68 | $222.11 | -2.9% | Buy | 20.6x | 37 |
Quick answers to the most common questions about buying SLP stock.
The consensus price target for SLP is $18.5, close to the current price of $18.28 (1.2% implied move). Based on 9 analyst estimates, the stock appears fairly valued near current levels.
SLP has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $18.5 implies 1.2% upside from current levels.
SLP trades at a forward P/E of 21.072x, representing a moderate valuation. With analysts targeting $18.5 (1.2% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $18.5 for SLP, while the most conservative target is $18.5. The consensus of $18.5 represents the median expectation. These targets typically reflect 12-month expectations.
SLP is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SLP stock forecast based on 9 Wall Street analysts shows a consensus price target of $18.5, with estimates ranging from $18.5 (bear case) to $18.5 (bull case). The median consensus rating is "Hold".
SLP trades at a forward P/E ratio of 21.1x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
SLP appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $18.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SLP analyst price targets range from $18.5 to $18.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $18.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.